Effect of autotransfusion system on tumor recurrence and survival in hepatocellular carcinoma patients

Table 2 Detailed tumor characteristics of liver-transplanted hepatocellular carcinoma patients in the continuous autotransfusion system and non-continuous autotransfusion system groups n (%)

Tumor characteristics	CATS group (n = 24)	Non-CATS group (n = 59)	P value
Tumor count
< 10	17 (70.8)	47 (79.6)	0.4
> 10	7 (29.2)	12 (20.3)
Mean tumor size, cm	5.8 ± 0.9	5.2 ± 0.5	0.7
Milan criteria
Within	8 (33.3)	22 (37.3)	0.7
Beyond	16 (66.6)	37 (62.7)
UCSF criteria
Within	9 (37.5)	29 (49.2)	0.3
Beyond	15 (62.5)	30 (50.8)
AFP levels
< 200	17 (70.8)	43 (73)	0.7
> 200	7 (29.2)	16 (27)
Tumor differentiation
Good	12 (50.0)	24 (41.0)	0.6
Average	9 (37.5)	23 (39.0)
Poor	3 (12.5)	12 (20.0)
Macrovascular invasion
Present	2 (8.4)	3 (5.0)	0.6
Absent	22 (91.6)	56 (95.0)
HCC recurrence
Present	7 (29.2)	15 (25.4)	0.7
Absent	17 (70.8)	44 (74.6)
Recurrence and/or metastasis
Hepatic	2	3	0.8
Extrahepatic	1	2
Both	4	10
Recurrence site
Liver	2	3
Lung	0	2
Liver + bone	1	0
Liver + lung	1	1
Liver + stomach	1	0
Liver + bone + lung	1	0
Lung + surrenal gland	1	0
Liver + surrenal gland	0	4
Liver + surrenal gland + lung	0	2	0
Liver + esophagus	0	1
Liver + lung + brain	0	1
Liver + surrenal gland + peritoneum	0	1

UCSF: University of California San Francisco; CATS: Continuous autotransfusion system; AFP: Alpha-fetoprotein; HCC: Hepatocellular carcinoma.